Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Vapendavir Formulations in Healthy Volunteers
NCT02877264Phase 1Completed
- Sponsor
- Aviragen Therapeutics
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Vapendavir in human rhinovirus infection (3 arms), sponsored by Aviragen Therapeutics. Primary endpoints: Relative oral bioavailability, Maximum observed plasma concentration and 2 more. Started Jun 2016; status: completed.
02
Drugs
Vapendavir
03
Conditions
human rhinovirus infection
Beyond the preview
Go deeper on NCT02877264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02877264.